Streetbeat News

Analyst Ratings

CE

Credit Suisse analyst John Roberts has maintained an 'Underperform' rating on Celanese (NYSE:CE) and raised the price target from $100 to $111.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:09 pm

MRVI

Credit Suisse analyst Dan Leonard has maintained a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and lowered the price target from $14 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:06 pm

IVR

Credit Suisse analyst Douglas Harter has reiterated an 'Underperform' rating on Invesco Mortgage Capital (NYSE:IVR) and maintained a price target of $10.5.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:05 pm

PAY

Paymentus Holdings, Inc. (NYSE:PAY) reported strong Q2 results, beating market estimates. The company's shares jumped 10.8% in pre-market trading. Analysts from Goldman Sachs and Raymond James have raised their price targets on Paymentus following the earnings announcement.

Portfolio Pulse from Lisa Levin

August 08, 2023 | 12:05 pm

HSIC

Credit Suisse analyst Jonathan Yong has reiterated an 'Outperform' rating on Henry Schein (NASDAQ:HSIC) and maintained a price target of $96.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:04 pm

NETI

Eneti (NYSE:NETI) reported Q2 adjusted earnings of $0.08 per share, beating the analyst consensus estimate of $0.06 by 33.33%. However, the company's quarterly sales of $38.85 million missed the analyst consensus estimate of $38.98 million by 0.34%, marking a 36.61% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:04 pm

CRSP

Credit Suisse analyst Richard Law maintains a Neutral rating on CRISPR Therapeutics (NASDAQ:CRSP) and raises the price target from $62 to $63.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:04 pm

OMI

Credit Suisse analyst Jonathan Yon maintains a Neutral rating on Owens & Minor (NYSE:OMI) and raises the price target from $18 to $19.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:03 pm

VRTV

Veritiv (NYSE:VRTV) reported Q2 earnings of $5.15 per share, beating the analyst consensus estimate of $5.02 by 2.59%. However, this is a 15.85% decrease from the same period last year. The company's quarterly sales were $1.46 billion, missing the analyst consensus estimate of $1.62 billion by 10.06%, and marking a 19.99% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:02 pm

UWMC

In the last quarter, 5 analysts have provided ratings for UWM Hldgs (NYSE:UWMC) with 1 being bullish, 2 indifferent, and 2 somewhat bearish. The company has an average 12-month price target of $4.9, up by 24.05% from the previous average of $3.95.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 12:01 pm